User profiles for "author:Sibylle Loibl"
sibylle loiblProfessor for medicine Verified email at gbg.de Cited by 86961 |
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino… - The Lancet, 2014 - thelancet.com
Background Pathological complete response has been proposed as a surrogate endpoint
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival …
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival …
[HTML][HTML] The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Evidence is strengthening for the morphological evaluation of tumor infiltrating lymphocytes
(TILs) in breast cancer. Herein, the concepts for TILs assessment are laid out by pathologists …
(TILs) in breast cancer. Herein, the concepts for TILs assessment are laid out by pathologists …
[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
HJ Burstein, G Curigliano, B Thürlimann, WP Weber… - Annals of oncology, 2021 - Elsevier
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
[HTML][HTML] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …
A Goldhirsch, EP Winer, AS Coates, RD Gelber… - Annals of oncology, 2013 - Elsevier
Abstract The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel
reviewed and endorsed substantial new evidence on aspects of the local and regional …
reviewed and endorsed substantial new evidence on aspects of the local and regional …
[PDF][PDF] Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
G Von Minckwitz, M Untch, JU Blohmer… - J Clin …, 2012 - aula.campuspanamericana.com
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant
Chemotherapy in Various Intrinsic Breast Ca Page 1 Definition and Impact of Pathologic Complete …
Chemotherapy in Various Intrinsic Breast Ca Page 1 Definition and Impact of Pathologic Complete …
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …
Background Pembrolizumab monotherapy showed durable antitumour activity and
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …
[HTML][HTML] Trastuzumab emtansine for residual invasive HER2-positive breast cancer
G Von Minckwitz, CS Huang, MS Mano… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients who have residual invasive breast cancer after receiving neoadjuvant
chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy …
chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy …
[HTML][HTML] Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
F André, E Ciruelos, G Rubovszky… - … England Journal of …, 2019 - Mass Medical Soc
Background PIK3CA mutations occur in approximately 40% of patients with hormone
receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast …
receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast …
[PDF][PDF] Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant
Chemotherapy in Breast Cancer Page 1 Tumor-Associated Lymphocytes As an …
Chemotherapy in Breast Cancer Page 1 Tumor-Associated Lymphocytes As an …
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
C Denkert, G von Minckwitz, S Darb-Esfahani… - The lancet …, 2018 - thelancet.com
Summary Background Tumour-infiltrating lymphocytes (TILs) are predictive for response to
neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive …
neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive …